HCPCS code J9299: Injection, nivolumab, 1 mg billing guide

Key Takeaways

HCPCS code J9299 describes injection, nivolumab, 1 mg (Opdivo), a PD-1 checkpoint inhibitor used in oncology infusion settings

Bill one unit per 1 mg of nivolumab administered – a 240 mg dose requires 240 units on the claim

CMS classifies J9299 as a single-dose container: Always append a JW or JZ modifier to document drug wastage or confirm no wastage occurred

Pabau’s claims management software supports structured infusion drug documentation, modifier tracking, and NDC reporting alongside J9299

HCPCS code J9299 is the billable Level II code for injection, nivolumab, 1 mg (Opdivo), a PD-1 checkpoint inhibitor administered intravenously in oncology infusion settings. One unit equals 1 mg of nivolumab administered.

This guide covers every billing element for J9299: code structure, unit calculation, administration CPT pairings, JW/JZ modifier requirements, NDC reporting, and payer reimbursement.

HCPCS code J9299: Description and drug overview

HCPCS code J9299 is the Level II code assigned by the Centers for Medicare and Medicaid Services (CMS) for the injection of nivolumab at 1 mg per unit.

The code falls under the Chemotherapy Drugs section of the HCPCS Level II code set. It is used across physician offices, hospital outpatient departments, and infusion centers billing Medicare Part B, Medicaid, and most commercial plans.

Nivolumab is marketed as Opdivo by Bristol Myers Squibb (BMS). It is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) receptor – a checkpoint protein that cancer cells exploit to evade immune destruction. The FDA first approved nivolumab in 2014, making it one of the earliest checkpoint inhibitors to reach clinical practice, according to the SEER CanMED HCPCS database.

The drug is administered intravenously and supplied in single-dose vials. Because CMS classifies J9299 as a single-dose container drug, any vial content discarded after the patient’s dose must be reported using the JW modifier. This single classification drives most of the compliance complexity around billing J9299.

J9299 code properties at a glance

The table below summarizes the key administrative properties of J9299 as maintained by CMS. Coders should verify code status annually, as HCPCS Level II codes are updated each January 1.

FDA-approved indications for nivolumab

Nivolumab has received multiple FDA approvals across cancer types since 2014. Billing J9299 for an unapproved indication without documented medical necessity and prior authorization is the most direct path to a denial. Only bill J9299 for FDA-approved uses or when a payer has granted specific authorization for an off-label indication through an established prior authorization process.

Approved indications span a wide oncology range and include:

• Unresectable or metastatic melanoma (As monotherapy or in combination with ipilimumab)
• Metastatic non-small cell lung cancer (NSCLC) — first-line in combination with ipilimumab, or as monotherapy for PD-L1-expressing tumors
• Advanced renal cell carcinoma — in combination with ipilimumab or as monotherapy
• Classical Hodgkin lymphoma (Relapsed or refractory after ASCT)
• Recurrent or metastatic squamous cell carcinoma of the head and neck
• Locally advanced or metastatic urothelial carcinoma
• Hepatocellular carcinoma (In combination with ipilimumab)
• Metastatic colorectal cancer with MSI-H or dMMR status
• Esophageal squamous cell carcinoma
• Gastric/gastroesophageal junction adenocarcinoma
• Pleural mesothelioma (Unresectable, first-line, with ipilimumab)

Documentation should explicitly link the submitted diagnosis ICD-10-CM code to an approved indication. Oncology practices using digital intake and consent forms can capture this linkage at the point of care.

The treating clinician’s notation of the specific cancer type and staging becomes part of the pre-authorization and claims support record.

Combination regimens with ipilimumab (Yervoy, billed under J9228) require separate line items on the CMS-1500 form for each drug, per BMS Access Support guidance.

HCPCS code J9299 units and dosage reporting

Unit calculation is where most J9299 billing errors occur. The code is defined as 1 mg per unit, so the number of units billed must equal the total milligrams of nivolumab actually administered to the patient.

How to calculate units

Nivolumab dosing follows weight-based or flat-dose protocols depending on the approved indication and regimen. Common dosing patterns include 240 mg every two weeks, 480 mg every four weeks, or weight-based dosing (e.g., 3 mg/kg). Convert the dose to milligrams and bill that number as units.

• 240 mg dose: Bill 240 units of J9299
• 480 mg dose: Bill 480 units of J9299
• 3 mg/kg for a 70 kg patient (210 mg): Bill 210 units of J9299

Round to the nearest whole milligram. Never bill fractional units. The units billed for the administered drug must appear on a separate line from any units billed for the JW waste amount – both lines carry J9299, but with different modifiers (see the modifier section below).

Medicaid unit limits

Medicaid policies add another layer. Louisiana Medicaid, for example, limits reimbursement for J9299 to no more than 240 units per date of service for providers whose specialty is not home infusion therapy or pharmacy, according to the Louisiana Department of Health’s July 2024 policy document.

State Medicaid unit limits vary. Verify your state’s current fee schedule and unit cap before submitting J9299 claims to Medicaid.

Practices managing oncology infusion documentation benefit from automated billing workflows that flag when a billed unit count exceeds common payer thresholds, reducing the likelihood of a post-payment audit finding. Pairing that automation with structured IV therapy best practices creates a defensible claim record from the first patient touchpoint.

NDC reporting alongside J9299

Many payers, including Medicare and most commercial insurers, require the National Drug Code (NDC) to appear on the claim alongside J9299. Report the NDC in the qualifier-quantity-unit format on the CMS-1500 form (Box 19 or using the NDC qualifier loop in electronic claims).

The NDC identifies the specific Opdivo vial purchased, linking the claim to the buy-and-bill transaction. Missing or incorrect NDC data is a common reason for J9299 claims to suspend for manual review.

Manage oncology infusion billing from one platform

Pabau's claims management tools support infusion drug documentation, modifier tracking, NDC reporting, and prior authorization workflows – all in one place. See how it works for your practice.

Book a demo

CPT codes used with J9299 for infusion administration

J9299 covers the drug only. Administration of the infusion requires separate CPT codes reported alongside the HCPCS drug code. Using the wrong CPT code for administration – or failing to include one altogether – results in a claim that pays only for the drug with no reimbursement for the clinical service.

Primary administration codes

The three chemotherapy infusion administration CPT codes most commonly paired with J9299 are:

• CPT 96413 — Chemotherapy administration, intravenous infusion technique; up to 1 hour, initial drug. Use this code for the first hour of nivolumab infusion when it is the initial drug administered in the encounter.
• CPT 96415 — Each additional hour of IV infusion beyond the first hour. Report one unit of 96415 for each additional hour, rounding to the nearest full hour.
• CPT 96417 — Sequential infusion of an additional drug. Use this code when nivolumab follows another drug already administered in the same encounter (For example, when ipilimumab is administered first and nivolumab is the sequential agent).

These three codes apply to intravenous infusion. When chemotherapy is given by a different route, a separate administration code such as CPT 96401 (subcutaneous or intramuscular administration) is reported instead.

According to BMS Access Support’s CMS-1500 tutorial, a standard Opdivo plus Yervoy infusion encounter bills CPT 96413 for Opdivo administration, CPT 96417 for Yervoy as the sequential agent, and CPT 96415 where additional infusion time is required. J9299 and J9228 appear as separate drug lines, each with their respective JW waste modifier lines.

Practices using IV therapy EMR workflows that automatically populate administration CPT codes based on documented infusion start and stop times reduce manual transcription errors significantly.

NCCI edit considerations

CMS National Correct Coding Initiative (NCCI) edits govern which CPT codes can be billed together on the same claim. For J9299 billing, NCCI edits most commonly surface when an office visit E/M code is reported on the same day as chemotherapy administration. Generally, a separately identifiable and documented E/M service may be reported with a modifier 25, but routine monitoring or pre-infusion assessment that is integral to the infusion service should not be billed separately. Review the current NCCI edit tables and your MAC’s LCD for specialty-specific guidance.

JW and JZ modifier requirements for J9299

CMS requires a JW or JZ modifier on single-dose container drugs billed under Medicare Part B. The JW modifier has been required since January 1, 2017; the JZ modifier became required on July 1, 2023. J9299 falls under this policy because Opdivo is supplied in single-dose vials.

Failure to append the correct modifier is a compliance issue, not just a billing inconvenience, and Medicare will reject J9299 claims that omit it. JW/JZ reporting is a Medicare requirement; commercial payer policies vary, so confirm each payer’s rules.

JW modifier (Drug wastage)

Append the JW modifier to a second J9299 line when any portion of the vial is discarded after the patient’s dose is administered. The JW line reports the wasted units.

For example, if a 100 mg vial is opened and only 80 mg is administered, the claim carries two J9299 lines: 80 units with no modifier (Administered dose) and 20 units with the JW modifier (Discarded waste).

Reimbursement for the JW line depends on payer policy. Medicare Part B typically reimburses the wasted portion to prevent providers absorbing the full vial cost when partial use is clinically required.

JZ modifier (No drug wastage)

When the full vial content is administered to the patient with no waste, append the JZ modifier to the single J9299 line. The JZ modifier serves as an attestation that no drug was discarded. CMS introduced the JZ modifier to eliminate the prior ambiguity where coders reported only the administered units without any modifier, making it impossible for payers to determine whether wastage occurred but was not billed.

Documentation requirements

The clinical record must support whichever modifier is used. For JW claims, the record should document the vial size opened, the dose administered, and the amount discarded. For JZ claims, documentation should confirm that the full vial content was used.

Oncology practices need a workflow that captures this information at the point of administration, not retroactively at the billing stage. Using prescription and drug management tools that record vial lot numbers, opening quantities, and administered amounts creates an automatic audit trail for modifier compliance.

The HIPAA-compliant documentation frameworks that govern electronic health records apply equally to drug wastage records. The key principle: document contemporaneously, at the time of administration, not after the fact. Retrospective correction of wastage records is an audit red flag.

Medicare and commercial payer reimbursement

Medicare Part B reimburses J9299 under the buy-and-bill model. The provider acquires the drug from a wholesaler or directly from BMS, administers it to the patient, and then bills Medicare for reimbursement.

Medicare’s payment rate is based on Average Sales Price (ASP) plus a percentage add-on, updated quarterly by CMS. Because ASP fluctuates with market pricing, the reimbursement rate for J9299 changes each quarter.

Always verify the current quarter’s J9299 rate before projecting revenue or communicating estimated patient liability. Use the CMS Physician Fee Schedule lookup tool or the Part B drug payment file on the CMS website for current ASP-based rates. Citing a prior quarter’s rate – even the previous quarter’s – creates patient communication and revenue cycle errors.

Commercial payer considerations

Commercial payers typically negotiate J9299 reimbursement rates independently of Medicare ASP. Rates vary significantly across contracts. Key considerations for commercial billing include:

• Prior authorization: Most commercial payers require prior authorization for nivolumab before the first infusion. Authorization requirements, clinical criteria, and step therapy requirements vary by plan and contract year. Never assume a prior authorization obtained for one regimen covers a new combination or indication.
• Step therapy: Some commercial plans require documented failure of first-line chemotherapy before approving nivolumab, even for indications where nivolumab is FDA-approved as first-line therapy. Verify each payer’s current medical policy.
• Specialty pharmacy benefit: A minority of commercial plans manage nivolumab under the pharmacy benefit rather than the medical benefit, requiring specialty pharmacy dispensing rather than buy-and-bill. Confirm benefit category at the time of authorization to avoid dispensing under the wrong benefit structure.
• Medicaid: Medicaid programs are state-administered. Coverage, authorization criteria, and unit limits (Such as Louisiana’s 240-unit cap) differ by state. Consult the applicable state Medicaid fee schedule and drug policy bulletin for each claim.

Oncology billing teams using compliance documentation tools can track prior authorization status, approval dates, and authorization unit limits alongside the patient’s infusion schedule.

When authorization covers a defined number of cycles, the billing system should flag when the patient approaches the authorization limit so the practice can initiate a renewal before the next scheduled infusion. The practice management systems best suited to oncology infusion handle this kind of multi-step authorization tracking natively rather than relying on manual spreadsheets.

Claim submission checklist for J9299

Before submitting a J9299 claim, verify each of the following. Missing any element creates a correctable denial that delays payment and adds rework to the revenue cycle.

• ICD-10-CM diagnosis code maps to an FDA-approved nivolumab indication or a payer-authorized off-label use
• Units billed equal the total milligrams administered (Not the vial size)
• JW or JZ modifier appended to J9299 on every claim (Mandatory for Medicare; commercial payer policies vary)
• NDC reported in the correct qualifier format on the claim form (Required by Medicare and most commercial payers)
• Administration CPT code (96413, 96415, or 96417) present and matched to the infusion documentation
• Prior authorization number included in the appropriate claim field (Box 23 on CMS-1500)
• Combination regimen: If J9228 (ipilimumab) is also administered, each drug appears on a separate line with its own JW/JZ modifier line
• Place of service code matches the billing entity type (Physician office vs. outpatient hospital)

Oncology and infusion practices can reduce claim errors by integrating this checklist into their pre-submission workflow inside a purpose-built IV therapy practice management platform. For broader revenue cycle context, practices evaluating their technology stack can review what oncology-compatible EMR platforms offer in terms of built-in coding validation and prior auth tracking.

Conclusion

Billing J9299 correctly requires more than knowing the code description. Unit precision, JW/JZ modifier compliance, NDC reporting, and prior authorization management each represent a separate failure point in the oncology claim workflow.

Pabau’s claims management software gives infusion and oncology practices a structured environment for documenting drug administration, tracking modifier requirements, and managing prior authorizations alongside the patient’s treatment record. To see how Pabau handles infusion billing workflows, book a demo with our team.

Continue your research

Managing complex infusion billing across multiple payers? Claims management software provides a structured workflow for modifier tracking, NDC reporting, and denial management in infusion settings.

Running an IV therapy or infusion practice? IV therapy EMR software covers scheduling, documentation, and billing workflows purpose-built for infusion providers.

Need a reference for other injectable drug codes? IVF CPT codes provides a comparable billing reference for injectable fertility drug procedures and administration codes.

Looking for coding resources for related oncology billing? Procedure code references across Pabau’s billing library cover a range of specialty drug and administration codes.

Frequently Asked Questions